Shares of TrovaGene, Inc. (NASDAQ:TROV) Spike as its PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga in Castration Resistant Prostate Cancer Tumor Cells

Shares of TrovaGene, Inc. (NASDAQ:TROV) Spike as its PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga in Castration Resistant Prostate Cancer Tumor Cells

Precision medicine biotechnology company, TrovaGene, Inc. (NASDAQ:TROV), announces that it has received positive data from preclinical research leading to a 9.873% jump in its share price. SAN DIEGO, Oct. 18, 2017 /PRNewswire/ — Trovagene, Inc. (NASDAQ: TROV), a precision medicine biotechnology company, today announced positive data from preclinical research demonstrating synergy of PCM-075, its oral, highly-selective Polo-like Kinase 1 (PLK1) Inhibitor, in combination with abiraterone (Zytiga® – Johnson & Johnson). […]

Read More ˃
Amedica, Corp. (NASDAQ:AMDA) Receives Positive Nasdaq Listing Decision, Share Price Explodes

Amedica, Corp. (NASDAQ:AMDA) Receives Positive Nasdaq Listing Decision, Share Price Explodes

Innovative biomaterial company that develops and manufactures silicon nitride as a platform for biomedical applications, Amedica, Corp. (NASDAQ:AMDA), has announced that the Nasdaq Hearings Panel has granted its request for an extension to provide evidence of full compliance. SALT LAKE CITY, Oct. 17, 2017 (GLOBE NEWSWIRE) — Amedica Corporation (AMDA) (the “Company”), an innovative biomaterial company that develops and manufactures silicon nitride as a platform for biomedical applications, announced today […]

Read More ˃